Mylan

Information

Name

Mylan

Type

Company

Roles

Supplier

Company Size

Sme

Company Number

Incorporation Date

Website

http://www.mylan.co.uk

Address

Hatfield

United Kingdom

Suppliers

Unlock the full supplier list, free!

Sign up to unlock the full list of suppliers associated with Mylan
Sign up free

Contracts awarded to Mylan

The contracts that Mylan have been awarded to supply. Click on the contract to view more detailed information and view the full details about the contract won.

Award

Published 6 months ago

NHS National Generic Pharmaceuticals Wave 14c (CF Award - Part 1)

Invitation to offer for NHS National Generic Pharmaceuticals - Wave 14c Offer reference number: CM/PHG/22/5672 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 36 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: Orals (plus non-parenteral) Products: All Regions (CESW/LSNE/NWLN):01/06/2024 to 31/05/2027 (36 Months) Hospital Only Products: DLS & DNE: 01/06/2024 to 31/05/2026(24 months) Hospital Only Products(Housekeeping): DLN & DNW: 01/06/2024 to 31/01/2025(8 months) DCE & DSW: 01/06/2024 to 30/09/2025(16 months)

£424,035,364 Bids close: 1 year ago
Award

Published 6 months ago

NHS National Framework for Transition products commencing 1 May 2024

Project title: NHS National Framework for Transition products commencing 1 May 2024 Offer reference number: CM/TNS/05/2024 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months. Potential periods of call-offs under the framework agreement: CM/TNS/05/2024/01 - Dimethyl fumarate, Teriflunomide, Trabectedin Lot 1 NWLN: 01/05/2024 to 31/01/2025 (9 months) Lot 2 CESW: 01/05/2024 to 30/09/2025 (17 months) Lot 3 LSNE: 01/05/2024 to 30/09/2025 (17 months) CM/TNS/05/2024/02 - Apixaban, Sapropterin Lot 1 DNW+DNE+DCE 01/05/2024 to 30/09/2025 (17 months) Lot 2 DLS+DLN+DSW 01/05/2024 to 30/09/2025 (17 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

£7,559,000 Bids close: 8 months ago
Award

Published 6 months ago

NHS National Framework for Transition products commencing 1 May 2024

Project title: NHS National Framework for Transition products commencing 1 May 2024 Offer reference number: CM/TNS/05/2024 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months. Potential periods of call-offs under the framework agreement: CM/TNS/05/2024/01 Lot 1 NWLN: 01/05/2024 to 31/01/2025 (9 months) Lot 2 CESW: 01/05/2024 to 30/09/2025 (17 months) Lot 3 LSNE: 01/05/2024 to 30/09/2025 (17 months) CM/TNS/05/2024/02 Lot 1 DNW+DNE+DCE 01/05/2024 to 30/09/2025 (17 months) Lot 2 DLS+DLN+DSW 01/05/2024 to 30/09/2025 (17 months) Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England

£14
Award

Published 7 months ago

NHS National Generic Pharmaceuticals Wave 14c

NHS National Generic Pharmaceuticals- Wave 14c Offer reference number: CM/PHG/22/5672 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 36 months with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: Orals (plus non-parenteral) Products: All Regions (CESW/LSNE/NWLN):01/06/2024 to 31/05/2027 (36 Months) Hospital Only Products: DLS & DNE: 01/06/2024 to 31/05/2026(24 months) Hospital Only Products(Housekeeping): DLN & DNW: 01/06/2024 to 31/01/2025(8 months) DCE & DSW: 01/06/2024 to 30/09/2025(16 months)

£219
Award

Published 8 months ago

NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024

Project Title: NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024 Offer reference number: CM/PHR/22/5678 CM/PHR/22/5678/01 - NHS Framework for NORTH OF ENGLAND Branded Medicines - Tranche B. Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5678/02 - NHS Framework for NORTH OF ENGLAND Branded Medicines (to transition to Tranche B) Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5678/03 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines - Tranche A. Period of framework: 1 March 2024 to 31 August 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months CM/PHR/22/5678/04 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines (to transition to Tranche B). Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months

£74
Award

Published 8 months ago

NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024

Project Title: NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024 Offer reference number: CM/PHR/22/5678 CM/PHR/22/5678/01 - NHS Framework for NORTH OF ENGLAND Branded Medicines - Tranche B. Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5678/02 - NHS Framework for NORTH OF ENGLAND Branded Medicines (to transition to Tranche B) Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5678/03 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines - Tranche A. Period of framework: 1 March 2024 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months CM/PHR/22/5678/04 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines (to transition to Tranche B). Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months

£580,156,000 Bids close: 1 year ago

Contacts

+44 7585600993

Statistics (1 Year)

Contracts Won

Total Won

£671,163

Average Win

£671,163

Mylan

Information

Name

Type

Roles

Company Size

Company Number

Incorporation Date

Website

Address

Suppliers

Contracts awarded to Mylan

NHS National Generic Pharmaceuticals Wave 14c (CF Award - Part 1)

NHS National Framework for Transition products commencing 1 May 2024

NHS National Framework for Transition products commencing 1 May 2024

NHS National Generic Pharmaceuticals Wave 14c

NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024

NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024

Contacts

Statistics (1 Year)

Contracts Won

Total Won

Average Win